Scroll Down Arrow

CIP Course for Advanced Learners – Biomedical and FDA Research Topics

This course provides advanced learners a topic-focused course on biomedical and U.S. Food and Drug Administration (FDA) research topics as well as 5 CE hours for CIP recertification.

ORGANIZATIONS

LEARN MORE

Learners

BUY NOW

Questions?

Contact Us


About this Course


The course is intended for currently Certified IRB Professionals (CIPs) seeking CIP continuing education (CE) credits for recertification. These modules were approved by the Council for Certification of IRB Professionals (CCIP) as advanced-level and eligible for CIP CE credits.

This course includes a topic-focused selection of CIP approved modules for recertification by education.

Learners can self-direct their training by choosing which and how many modules to complete in order to earn CIP CE credits.

Note: These modules (or a selection of them) may be part of an organization’s subscription.  If you are affiliated with a subscribing organization, it is recommended that you review the modules you may have access to via that subscription before purchasing this course.

Language Availability: English

Suggested Audiences: Certified IRB Professionals (CIPs)

Independent Learner Price: $99 per person


Course Content


FDA-Regulated Research

Addresses U.S. Food and Drug Administration-regulated clinical research and the responsibilities of researchers, IRBs, and sponsors when an FDA-regulated product is utilized in a study. In particular, it includes information on when an Investigational New Drug (IND) application is necessary and the requirements of Form FDA 1572. Medical devices research, including defining a medical device, classifying risk, and when an investigational device exemption (IDE) is needed are also presented. Lastly, it addresses FDA regulations about informed consent, emergency use, and 21 CFR Part 11 and electronic records and signatures.

Recommended Use: Elective
ID (Language): 12 (English)
Author(s): Susan Kornetsky, MPH - Children's Hospital, Boston; David G. Forster, JD, MA, CIP - Western IRB; Gary L. Chadwick, PharmD, MPH, CIP - The University of Rochester

Humanitarian Use Devices (HUDs)

Provides a basic overview of the U.S. Food and Drug (FDA) regulations and responsibilities regarding HUDs. It describes the HUD program and Humanitarian Device Exemption (HDE) regulatory process, and explains the applicable requirements and differences between 1) a “clinical use” of a HUD to treat or diagnose patients or 2) a “HUD investigation.” It also categorizes the FDA regulations and IRB review requirements for HUD investigations within and outside of the HDE approved indications, and identifies additional federal rules or institutional requirements that may apply to the clinical use of a HUD or HUD investigations.

Recommended Use: Elective
ID (Language): 16306 (English)
Author(s): Belinda Smith, MS, RD, CCRC - University of Kentucky; Kevin L. Nellis, MS, CIP - Maimonides Medical Center; Ada Sue Selwitz, MA - University of Kentucky

Data and Safety Monitoring in Human Subjects Research

Describes approaches to monitoring the emerging results of an ongoing study, the different types of study data that are monitored, and the role and operational procedures of independent monitoring groups and how they relate to other study oversight entities. It also explains regulatory requirements and other policies related to study monitoring and discusses similarities and differences between the Institutional Review Board (IRB) and the Data Safety Monitoring Board (DSMB). Reviews the basic elements of data safety monitoring plans and DSMBs.

Recommended Use: Elective
ID (Language): 17433 (English)
Author(s): Susan S. Ellenberg, PhD - University of Pennsylvania; Susan S. Fish, PharmD, MPH - Boston University; Stephen M. Davis, MPA, MSW - West Virginia University

Consent and Biobanks and Associated Databases

Describes different consent approaches used for biobanks and associated databases, with reference to pertinent legal and ethical documents and regulatory requirements. Additionally, learners will review examples of key consent clauses (for example, linkage, return of research results and incidental findings, storage for future use, and access by researchers). Reviews the diversity, nature, and characteristics of biobanks and associated databases.

Recommended Use: Elective
ID (Language): 17254 (English)
Author(s): Bartha Maria Knoppers, PhD - McGill University; Ma’n H. Zawati, LLM - McGill University

Phase I Research: Understanding Phase I Research

Defines phase I research as it relates to non-clinical and other phases of research. Identifies routine study designs used to develop the initial safety profile and achieve study objectives in phase I research. Reviews the importance of phase I research on drug development.

Recommended Use: Elective
ID (Language): 16873 (English)
Author(s): Julie Blasingim, BA, MBA, CIP - Schulman Associates IRB

Phase I Research: Protecting Phase I Subjects

Reviews U.S. Food and Drug Administration (FDA) requirements for initiation of phase I research studies following non-clinical studies. Describes IRB considerations for review of phase I research. Identifies ways in which researchers and staff involved in phase I research can apply the necessary safeguards to protect subjects including selecting a safe starting does, safeguards for standard dosing regimens, selecting appropriate subjects, facility safeguards, and the role of informed consent.

Recommended Use: Elective
ID (Language): 16874 (English)
Author(s): Julie Blasingim, BA, MBA, CIP - Schulman Associates IRB

Stem Cell Research Oversight (Part I)

Introduces the nature and characteristics of both adult and embryonic stem cells. It reviews the requirements of the federal regulations associated with stem cell research and the role of both state and local requirements. It also discusses the contentious historical and ethical issues surrounding stem cell research and the clinical application of stem cells.

Recommended Use: Elective
ID (Language): 13882 (English)
Author(s): David A. Crouse, PhD - University of Nebraska Medical Center (ret.); Ruth L. Fischbach, PhD, MPE - Columbia University; Gwenn S.F. Oki, MPH, CIP - Van Andel Institute

Stem Cell Research Oversight (Part II)

Builds on the content presented in Part 1 and provides a framework for institutional review of stem cell research, national guidelines as well as current federal law and policy. It provides an overview of the National Academy of Sciences (NAS), International Society for Stem Cell Research (ISSCR), and National Institutes of Health (NIH) guidelines related to human stem cell research and research involving human subjects. Consideration is given to U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) regulatory requirements, Stem Cell Research Oversight (SCRO) committee composition and responsibilities, categories of research, and a comprehensive definition of provenance as it applies to human stem cell research. A detailed overview of the recommendations of the NAS, ISSCR, and NIH Guidelines as well as information related to the procurement, banking, and use of human stem cell lines are provided via the hyperlinks at the end.

Recommended Use: Elective
ID (Language): 14584 (English)
Author(s): Ruth Fischbach, PhD, MPE - Columbia University; Gwenn Oki, MPH, CIP - Van Andel Institute

Informed Consent and Incidental Findings in Research with Human Subjects New Content

Defines incidental findings (IFs) in human subjects research and covers how IFs should be managed in the informed consent process. Provides an overview of Institutional Review Board (IRB) and researcher responsibilities, as well as strategies for managing IFs in the consent process, including review of the research plan, IF management plan, and consent form language.

Recommended Use: Elective
ID (Language): 17342 (English)
Author(s): Diane Paul, MS, RN - Drug Development Associates, LLC

Consent and Subject Recruitment Challenges: Therapeutic Misconception New Content

Describes therapeutic misconception and identifies potential strategies researchers and institutional review board (IRB) members can use for reducing therapeutic misconception in the consent process. Identifies groups of people at risk for therapeutic misconception and their vulnerabilities. Also discussed are the related phenomena of therapeutic misestimation and therapeutic optimism.

Recommended Use: Elective
ID (Language): 17259 (English)
Author(s): Moore Rhys, BA, CIP - Children's Hospital Los Angeles


FAQs


Who is eligible for earning CIP CE credits?

Certified IRB Professionals (CIPs) may earn CIP CE credits by completing eligible modules.

Which modules are eligible for CIP CE credits?

See CITI Program Advanced-Level Modules Eligible for CIP Continuing Education Credits for a complete list of CIP CE certified modules.

Are all modules in this course eligible for CIP CE credits?

Yes.

How many CIP CE credits are available by completing this course?

Each successfully completed CITI Program advanced-level module represents half a CIP CE credit (0.5 credit). For example, a learner that completes 8 modules qualifies for 4 CIP CE credits.

What is the passing score requirement for CIP CE credits?

A minimum quiz score of 70% is required for each module.

How can learners document their CIP CE credits?

Learners who wish to apply the credits from approved modules toward their CIP recertification may submit their CITI Program Completion Report as documentation of their participation (the transcript page will have a record of each module and date completed). Completion Reports identify the learner’s name, and the module titles, IDs, completion dates, and quiz scores.

Where can learners find additional information about CIP recertification?

See CIP Recertification on PRIM&R’s website for additional information about CIP recertification.